Clinical Trials
Retinal Disorders

Disease/ Subspecialty:

Diabetic Retinopathy

Principal Investigator:

Richard Alan Lewis, M.D.

Contact:

Email Retinal-Trials@bcm.edu

Enrollment:

Closed

Sponsor:

Eli Lilly and Company

Title:

Protein kinase C beta inhibitor-diabetic retinopathy study 2. A phase III clinical trial

IRB Protocol #:

H-9636

Disease/ Subspecialty:

Retinal Disorders

Principal Investigator:

Eric R. Holz, M.D.

Contact:

email Retinal-Trials@bcm.tmc.edu

Enrollment:

Yes

Sponsor:

Eyetech Pharmaceuticals

Title:

A phase II randomized, controlled, double-masked dose-finding multi-center, comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001(Anti-Vegf Pegylated Aptamer), given every 6 weeks for 12 t0 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula.

IRB Protocol #:

H-12868
home | contact us | bcm public | bcm intranet | privacy notices
about us:
faculty | background | history | facilities
patient care:
meet our physicians | request an appointment | prescription refill | financial policy | directions/ find us | amenities | patient education | FAQ
referring physicians:
meet our physicians | request an appointment | request for information | grand rounds schedule | continuing medical education | FAQ
education:
grand rounds schedule | medical students | resident applicants | fellowship applicants
research/ clinical trials:
cataract | dry eye disease | genetics | glaucoma | hiv/ aids | laser vision correction | macular degeneration | pediatric eye disorders | retinal disorders
giving | links

©2001 Department of Ophthalmology - Baylor College of Medicine
http://www.bayloreye.org/trials/pedi.html